Although the application of venovenous extracorporeal membrane oxygenation (VV-ECMO) in coronavirus disease 2019 (COVID-19) patients with acute respiratory distress syndrome (ARDS) is accumulating, the feasibility and safety of this therapy remain controversial. We aimed to evaluate the effect of VV-ECMO in the treatment of these patients.
Methods
A comprehensive literature search was performed using PubMed, Embase, the Cochrane Library, and International Clinical Trials Registry Platform databases through November 2021. According to the inclusion and exclusion criteria, the included studies were screened, and meta-analysis was performed by R software (version 4.0.2).
Results
Forty-two studies including 2037 COVID-19 patients supported with VV-ECMO due to ARDS were identified. The pooled analysis revealed that 30-, 60-, and 90-day mortality among patients were respectively 46% (95% CI 37%–57%, I2 = 66%), 46% (95% CI 30%–70%, I2 = 93%), and 49% (95% CI 43%–58%, I2 = 52%), and the pooled incidence rate of in-hospital mortality, major bleeding, hemorrhagic stroke, thrombosis, pulmonary embolism, deep venous thrombosis, and renal replacement therapy were respectively 35%, 39%, 11%, 40%, 15%, 21%, and 44%.
Conclusion
Although COVID-19 patients may have a higher risk of bleeding, hemorrhagic stroke, and acute kidney injury during ECMO therapy, the survival rate was more than half of the cases. Our data may support the application of VV-ECMO in COVID-19 patients.
HenryBMLippiG. Poor survival with extracorporeal membrane oxygenation in acute respiratory distress syndrome (ARDS) due to coronavirus disease 2019 (COVID-19): pooled analysis of early reports. J Crit Care2020; 58: 27–28.
5.
RichardsonSHirschJSNarasimhanM, et al.Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York city area. JAMA2020; 323: 2052–2059.
6.
GuanWJNiZYHuY, et al.Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med2020; 382: 1708–1720.
7.
ZhouFYuTDuR, et al.Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet2020; 395: 1054–1062.
8.
CombesAHajageDCapellierG, et al.Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome. N Engl J Med2018; 378: 1965–1975.
9.
GoligherECTomlinsonGHajageD, et al.Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome and posterior probability of mortality benefit in a post hoc Bayesian analysis of a randomized clinical trial. JAMA2018; 320: 2251–2259.
10.
MunshiLWalkeyAGoligherE, et al.Venovenous extracorporeal membrane oxygenation for acute respiratory distress syndrome: a systematic review and meta-analysis. Lancet Respir Med2019; 7: 163–172.
11.
AlhazzaniWMøllerMHArabiYM, et al.Surviving sepsis campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). Crit Care Med2020; 48: e440–e469.
12.
BadulakJAntoniniMVSteadCM, et al.Extracorporeal membrane oxygenation for COVID-19: updated 2021 guidelines from the Extracorporeal Life Support Organization. ASAIO J2021; 67: 485–495.
13.
SchmidtMHajageDLebretonG, et al.Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome associated with COVID-19: a retrospective cohort study. Lancet Respir Med2020; 8: 1121–1131.
14.
BarbaroRPMacLarenGBoonstraPS, et al.Extracorporeal membrane oxygenation support in COVID-19: an international cohort study of the Extracorporeal Life Support Organization registry. Lancet2020; 396: 1071–1078.
15.
BarbaroRPMacLarenGBoonstraPS, et al.Extracorporeal membrane oxygenation for COVID-19: evolving outcomes from the international Extracorporeal Life Support Organization Registry. Lancet2021; 398: 1230–1238.
16.
HigginsJPAltmanDGGotzschePC, et al.The Cochrane collaboration s tool for assessing risk of bias in randomised trials. BMJ2011; 343: d5928.
17.
MunnZBarkerTHMoolaS, et al.Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. JBI Evid Synth2020; 18: 2127–2133.
18.
CortegianiACrimiCSanfilippoF, et al.High flow nasal therapy in immunocompromised patients with acute respiratory failure: a systematic review and meta-analysis. J Crit Care2019; 50: 250–256.
19.
AlnababtehMHashmiMDVedantamK, et al.Extracorporeal membrane oxygenation for COVID-19 induced hypoxia: Single-center study. Perfusion2021; 36: 564–572.
20.
AutschbachTHatamNDurakK, et al.Outcomes of extracorporeal membrane oxygenation for acute respiratory distress syndrome in COVID-19 patients: a propensity-matched analysis. J Clin Med2021; 10: 2547.
21.
BergmanZRWotheJKAlwanFS, et al.Risk factors of mortality for patients receiving venovenous extracorporeal membrane oxygenation for COVID-19 acute respiratory distress syndrome. Surg Infect (Larchmt)2021; 22: 1086–1092.
22.
BermeaRSRazYSerticF, et al.Increased intracranial hemorrhage amid elevated inflammatory markers in those with COVID-19 supported with extracorporeal membrane oxygenation. Shock2021; 56: 206–214.
23.
BeylsCHuettePAbou-ArabO, et al.Extracorporeal membrane oxygenation for COVID-19-associated severe acute respiratory distress syndrome and risk of thrombosis. Br J Anaesth2020; 125: e260–e262.
24.
BiancariFMariscalcoGDalénM, et al.Six-month survival after extracorporeal membrane oxygenation for severe COVID-19. J Cardiothorac Vasc Anesth2021; 35: 1999–2006.
25.
BlazoskiCMBaramMYangQ, et al.Outcomes of extracorporeal membrane oxygenation in influenza versus COVID-19 during the first wave of COVID-19. J Card Surg2021; 36: 3740–3746.
26.
BohmanJKNeiSDMellonLN, et al.Physical therapy and sedation while on extracorporeal membrane oxygenation for COVID-19-associated acute respiratory distress syndrome. J Cardiothorac Vasc Anesth2021; 36(2): 524–528.
27.
Le BretonCBessetSFreita-RamosS, et al.Extracorporeal membrane oxygenation for refractory COVID-19 acute respiratory distress syndrome. J Crit Care2020; 60: 10–12.
28.
ChandelAPatoliaSLoobyM, et al.Association of D-dimer and fibrinogen with hypercoagulability in COVID-19 requiring extracorporeal membrane oxygenation. J Intensive Care Med2021; 36: 689–695.
29.
CousinNBourelCCarpentierD, et al.SARS-CoV-2 versus influenza-associated acute respiratory distress syndrome requiring veno-venous extracorporeal membrane oxygenation support. ASAIO J2021; 67: 125–131.
30.
DiazRAGrafJZambranoJM, et al.Extracorporeal membrane oxygenation for COVID-19-associated severe acute respiratory distress syndrome in Chile: a nationwide incidence and cohort study. Am J Respir Crit Care Med2021; 204: 34–43.
31.
DreierEMalfertheinerMVDienemannT, et al.ECMO in COVID-19-prolonged therapy needed? A retrospective analysis of outcome and prognostic factors. Perfusion2021; 36: 582–591.
32.
GarfieldBBianchiPArachchillageD, et al.Six month mortality in patients with COVID-19 and non-COVID-19 viral pneumonitis managed with veno-venous extracorporeal membrane oxygenation. ASAIO J2021; 67: 982–988.
33.
GuihaireJOwyangCGMadhokJ, et al.Specific considerations for venovenous extracorporeal membrane oxygenation during coronavirus disease 2019 pandemic. ASAIO J2020; 66: 1069–1072.
34.
HuettePBeylsCGuilbartM, et al.Extracorporeal membrane oxygenation for respiratory failure in COVID-19 patients: outcome and time-course of clinical and biological parameters. Can J Anaesth2020; 67: 1486–1488.
35.
JäckelMRilingerJLangCN, et al.Outcome of acute respiratory distress syndrome requiring extracorporeal membrane oxygenation in Covid-19 or influenza: a single-center registry study. Artif Organs2021; 45: 593–601.
36.
JacobsJPStammersAHSt LouisJD, et al.Multi-institutional analysis of 200 COVID-19 patients treated with ECMO: outcomes and trends. Ann Thorac Surg2021; 113(5): 1452–1460.
37.
JozwiakMChicheJDCharpentierJ, et al.Use of venovenous extracorporeal membrane oxygenation in critically-ill patients with COVID-19. Front Med (Lausanne)2020; 7: 614569.
38.
KannapadiNVJamiMPremrajL, et al.Neurologic injury in patients with COVID-19 who receive VV-ECMO therapy: a cohort study. J Cardiothorac Vasc Anesth2021; 35: 3456–3461.
39.
KonZNSmithDEChangSH, et al.Extracorporeal membrane oxygenation support in severe COVID-19. Ann Thorac Surg2021; 111: 537–543.
40.
LebretonGSchmidtMPonnaiahM, et al.Extracorporeal membrane oxygenation network organisation and clinical outcomes during the COVID-19 pandemic in Greater Paris, France: a multicentre cohort study. Lancet Respir Med2021; 9: 851–862.
41.
LoforteADi MauroMPellegriniC, et al.Extracorporeal membrane oxygenation for COVID-19 respiratory distress syndrome: an Italian society for cardiac surgery report. ASAIO J2021; 67: 385–391.
42.
MarcusJESamsVGBarsoumianAE. Elevated secondary infection rates in patients with coronavirus disease 2019 (COVID-19) requiring extracorporeal membrane oxygenation. Infect Control Hosp Epidemiol2021; 42: 770–772.
43.
MasiPTuffetSBoyerL, et al.Short and long-term outcomes of patients with COVID-19-associated acute respiratory distress syndrome and difficult veno-venous-ECMO weaning. Crit Care2021; 25: 337.
44.
MasurJFreemanCWMohanS. A double-edged sword: neurologic complications and mortality in extracorporeal membrane oxygenation therapy for COVID-19-related severe acute respiratory distress syndrome at a tertiary care center. AJNR Am J Neuroradiol2020; 41: 2009–2011.
45.
MustafaAKAlexanderPJJoshiDJ, et al.Extracorporeal membrane oxygenation for patients with COVID-19 in severe respiratory failure. JAMA Surg2020; 155: 990–992.
46.
NatanovRWiesnerOHaverichA, et al.Mechanical circulatory support in coronavirus disease-2019-positive patients with severe respiratory failure. Interact Cardiovasc Thorac Surg2021; 33: 489–493.
47.
OguraTOhshimoSLiuK, et al.Establishment of a disaster management-like system for COVID-19 patients requiring veno-venous extracorporeal membrane oxygenation in Japan. Membranes (Basel)2021; 11: 625.
48.
PellegriniJASSchwarzPParoloE, et al.Selecting candidates for veno-venous ECMO during COVID-19 pandemic: the importance of an ECMO team. Perfusion2021; 36: 640–642.
49.
RaffLAReidTDJohnsonD, et al.Comparative outcomes between COVID-19 and influenza patients placed on veno-venous extracorporeal membrane oxygenation for severe ARDS. Am J Surg2021.
50.
RhoadesRLeongRKopenitzJ, et al.Coagulopathy monitoring and anticoagulation management in COVID-19 patients on ECMO: Advantages of a heparin anti-Xa-based titration strategy. Thromb Res2021; 203: 1–4.
51.
RipollBRubinoABesserM, et al.Observational study of thrombosis and bleeding in COVID-19 VV ECMO patients. Int J Artif Organs2021; 45: 239–242.
52.
ShihEDiMaioJMSquiersJJ, et al.Venovenous extracorporeal membrane oxygenation for patients with refractory coronavirus disease 2019 (COVID-19): multicenter experience of referral hospitals in a large health care system. J Thorac Cardiovasc Surg2020; 163(3): 1071–1079.
53.
SupadyADellaVolpeJTacconeFS, et al.Outcome prediction in patients with severe COVID-19 requiring extracorporeal membrane oxygenation-a retrospective international multicenter study. Membranes (Basel)2021; 11: 170.
54.
SupadyATacconeFSLepperPM, et al.Survival after extracorporeal membrane oxygenation in severe COVID-19 ARDS: results from an international multicenter registry. Crit Care2021; 25: 90.
55.
SupadyAWeberERiederM, et al.Cytokine adsorption in patients with severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation (CYCOV): a single centre, open-label, randomised, controlled trial. Lancet Respir Med2021; 9: 755–762.
56.
TabatabaiAGhneimMHKaczorowskiDJ, et al.Mortality risk assessment in COVID-19 venovenous extracorporeal membrane oxygenation. Ann Thorac Surg2021; 112: 1983–1989.
57.
WeatherillALaffanMGasperM, et al.Impact of thrombosis and bleeding in patients with severe COVID-19 versus other viral pneumonias in the context of extracorporeal membrane oxygenation. Semin Thromb Hemost2021; 48: 118–123.
58.
YangXHuMYuY, et al.Extracorporeal membrane oxygenation for SARS-CoV-2 acute respiratory distress syndrome: a retrospective study from Hubei, China. Front Med (Lausanne)2021; 7: 611460.
59.
YankahCATrimlettRSandovalE, et al.COVID-19 pulmonary failure and extracorporeal membrane oxygenation: first experience from three european extracorporeal membrane oxygenation centers. Thorac Cardiovasc Surg2021; 69: 259–262.
60.
ZhangJMerrickBCorreaGL, et al.Veno-venous extracorporeal membrane oxygenation in coronavirus disease 2019: a case series. ERJ Open Res2020; 6(4): 00463–2020.
61.
HuiDSI AzharEMadaniTA, et al.The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - the latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis2020; 91: 264–266.
62.
HuangCWangYLiX, et al.Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet2020; 395: 497–506.
63.
CummingsMJBaldwinMRAbramsD, et al.Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York city: a prospective cohort study. Lancet2020; 395: 1763–1770.
64.
AoyamaHUchidaKAoyamaK, et al.Assessment of therapeutic interventions and lung protective ventilation in patients with moderate to severe acute respiratory distress syndrome: a systematic review and network meta-analysis. JAMA Netw Open2019; 2: e198116.
65.
PeekGJMugfordMTiruvoipatiR, et al.Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial. Lancet2009; 374: 1351–1363.
66.
BrodieDSlutskyASCombesA. Extracorporeal life support for adults with respiratory failure and related indications: a review. JAMA2019; 322: 557–568.
67.
JiménezDGarcía-SanchezARaliP, et al.Incidence of VTE and bleeding among hospitalized patients with coronavirus disease 2019: a systematic review and meta-analysis. Chest2021; 159: 1182–1196.
68.
ChoSMCannerJChiariniG, et al.Risk factors of ischemic and hemorrhagic strokes during venovenous extracorporeal membrane oxygenation: analysis of data from the Extracorporeal Life Support Organization registry. Crit Care Med2020; 48: e897–905.
69.
BikdeliBMadhavanMVJimenezD, et al.COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. J Am Coll Cardiol2020; 75: 2950–2973.
70.
HelmsJTacquardCSeveracF, et al.High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med2020; 46: 1089–1098.
71.
TangNLiDWangX, et al.Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost2020; 18: 844–847.
72.
FalcozPEMonnierAPuyraveauM, et al.Extracorporeal membrane oxygenation for critically ill patients with COVID-19-related acute respiratory distress syndrome: worth the effort?Am J Respir Crit Care Med2020; 202: 460–463.
73.
RoncoCReisTHusain-SyedF. Management of acute kidney injury in patients with COVID-19. Lancet Respir Med2020; 8: 738–742.
74.
DiaoBWangCWangR, et al.Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 infection. Nat Commun2021; 12: 2506.
75.
SilverSABeaubien-SoulignyWShahPS, et al.The prevalence of acute kidney injury in patients hospitalized with COVID-19 infection: a systematic review and meta-analysis. Kidney Med2021; 3: 83–98.
76.
GabarrePDumasGDupontT, et al.Acute kidney injury in critically ill patients with COVID-19. Intensive Care Med2020; 46: 1339–1348.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
